Dr Peter Ackerman presented the recent results of the BRIGHTE study – an analysis of the prodrug fostemsavir as an attachment inhibitor against HIV. Metabolism to the active moiety temsavir is via the gastrointestinal tract and it has been designed specifically for HIV-1 infected heavily treatment-experienced patients (HTP) who are failing their current therapy. In the BRIGHTE study, 86% of patients coming into the trial had a prior history of AIDS.
Dr Graeme Meintjes presents an overview of diagnostic and prevention issues in adult patients with HIV-associated tuberculosis. Estimates for 2017 showed that approximately 10% of global TB cases occurred in HIV infected people. This group also displays a disproportionately high TB mortality rate. However, incidence rates of HIV-associated TB have declined over the last decade.
Dr Zvi Cohen presents the phase 3 trial results of ibalizumab in heavily treatment experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen; ibalizumab was approved by the FDA in March 2018 for this patient population. Results from the Week 25 study (TMB-301) along with the Week 48 expanded access (completer) study (TMB-311) are discussed.
Dr Jay Grobler presents the latest data on MK-8591, a novel nucleoside with a unique mechanism of action. This first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) inhibits HIV replication through multiple mechanisms.